Considering that myeloid activation is a key feature of systemic juvenile idiopathic arthritis (sJIA) and macrophage activation syndrome [173,174], GM-CSF inhibition merits investigation in pediatric populations exhibiting severe disease phenotypes. The gene discussed is CSF2; the disease is juvenile idiopathic arthritis.